Asep Medical has finalised an exclusive licensing arrangement with the University of British Columbia (UBC) for a patented artificial intelligence (AI)-driven sepsis diagnosis technology.

The technology enables accurate diagnosis of sepsis disease at an early stage.

The patent arrangement provides Sepset Biosciences, a subsidiary of Asep, with exclusive rights to the technology, allowing them to develop the sepsis severity endotypes into a diagnostic test and launch it in the market.

Sepsis is said to be a difficult-to-diagnose disease due to extensive variability in symptoms and outcomes.

With the new SepsetER diagnostic tool, Asep Medical will help physicians understand sepsis disease severity and provide immediate treatment options for patients.

The blood-based gene expression assay is designed to sense the dysfunctional immune response underlying sepsis when patients enter the emergency room.

It provides results in about an hour in the emergency room or intensive care unit.

Asep Medical chairman and CEO Rudy Mazzocchi said: “We are extremely pleased with the continued partnership with UBC and their valuable role in expanding our patent portfolio and advancing our technologies as we make plans for the initiation of clinical studies to support a regulatory filing for commercial approval later this year.

“We have a controlling interest in Sepset Biosciences and the subsidiary is well funded and tasked with taking this groundbreaking technology to market quickly and efficiently.”

According to the company, sepsis caused nearly 11 million deaths across the world in 2017 and is also said to be a major contributing factor in Covid-19 morbidity.

The most severe form of the disease occurs in up to one-half of all hospitalised patients with Covid-19.